54P - Overall survival in patients with metastatic lung cancer from 2000 to 2020: Implementation of innovative strategies in a real-world setting

Background

Lung cancer burden on cancer related mortality is prominent. Over the past 20 years, innovative treatments have changed the outcome of patients. When global survival datas are reported through clinical trials, and national or international epidemiological registries, limited real-life data exists with regards to the actual evolution of survival focusing on patients with metastatic lung cancer over a long range of time.

Methods

We retrospectively analyzed the outcomes of all consecutive patients with a new diagnosis of primary metastatic lung cancer who were treated at Institut Curie from 2000 to 2020. We used the data software CONSORE running at the Institut since 2000. We anticipated to divide the period in three according to the implementation of major strategies in the first-line setting: 1) 2000-2009: platinum-based chemotherapy doublet; 2)2010-2017: EGFR tyrosine kinase inhibitors; 3) 2018-2020: immune checkpoint inhibitors. The date of diagnosis was used to allocate the patients. Overall survival (OS) and conditional survival were analyzed per period in the global cohort and in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

Results

670 patients were identified for the 1^st period (2000-2009), 747 patients for the 2^nd period (2010-2016) and 752 patients for the 3^rd period (2017-2020). The median OS was 11.1, 16.6, and 19.1months, respectively. Median OS for patients with SCLC was 9.9, 10.6, and 11.1 months, respectively; median OS for patients with NSCLC was 11.4, 19.2, and 24.8 months, respectively. The conditional survival to be alive at 24months if the patient was still alive at 6 months post diagnosis was 37.5%, 52.7% and 64.4% respectively for the three periods considering patients with NSCLC; whereas is was 21.3%, 22.2% and 37% respectively for the three periods considering SCLC.

Conclusions

Survival of patients with metastatic lung cancer has improved over the past 20 years, through the implementation of new treatment strategies. Achievement of median OS of 2 years has been reached in NSCLC, not in SCLC so far.

Legal entity responsible for the study

Prof. Nicolas Girard.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.